Berlin-based AMBOSS, a medical education and clinical decision-making platform, has closed a €240M financing round.
The investment includes new long-term investors and will support the company’s expansion into additional international markets. AMBOSS also plans to extend its offerings to nurses and other healthcare professionals.
New long-term investors
AMBOSS has changed its legal structure to a European stock corporation (SE) and secured funding from new investors. KIRKBI, M&G Investments, and Lightrock led the financing round, with support from existing shareholders.
Peter Bason, Head of Private Capital at KIRKBI, says, “We have followed AMBOSS’ impressive growth journey, from its successful US expansion to its strong focus on innovation. Its unique platform is becoming a vital tool for both medical students and healthcare professionals, supporting learning and decision-making at every stage.”
“We are excited to partner with other experienced technology and growth investors to back AMBOSS’ visionary leadership team in their mission of empowering the next generation of healthcare professionals worldwide.”
Empowering doctors to provide the best possible care
Founded in 2012 by physicians Dr. Madjid Salimi and Benedikt Hochkirchen, AMBOSS is a medical technology company that provides medical knowledge for students and clinicians.
Its platform offers an interactive library and question bank for study and exam preparation, while clinicians rely on evidence-based recommendations for clinical decision-making.
The platform integrates medical expertise and technology to support clinical decision-making. It provides diagnostic and treatment recommendations based on current guidelines, helping clinicians save time and reduce errors.
AI technologies play a role in ensuring reliable support for educators and healthcare professionals. “Technology will not replace health care professionals, but those who embrace it will lead the way,” says co-founder Dr. Salimi.
AMBOSS serves over 1 million professionals in 180 countries and has a team of more than 500 employees, including scientists, software engineers, and over 150 physicians.
In Germany, physicians use AMBOSS in half of all inpatient treatments. In the US, most medical students use AMBOSS for exam preparation, and 25 per cent of first-year residents depend on it for patient care.
Capital utilisation
Benedikt Hochkirchen, co-founder and co-CEO of AMBOSS, says, “We choose investors who are committed to our long-term vision and very flexible in the investment duration. Many of our new investors manage evergreen funds and plan to accompany us until a possible IPO and beyond.”
“Additional funds will go into further investment in technology and new market segments. Selective acquisitions will also continue to be part of our strategy.”
In 2024, AMBOSS expanded by acquiring Novaheal, a company focused on nursing, and NEJM Knowledge+, a board exam preparation platform for medical residents in the US. The latest financing round provides AMBOSS with increased capital to support its growth and initiatives.
01
destream: Building the financial backbone of the creator economy